Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Subsequent offering of NOK 5 million completed

Reference is made to stock exchange notice published on 26 April 2016 regarding subsequent offering of NOK 5,000,000. The subscription period ended 10 May 2016. Induct has received subscriptions amounting to NOK 7,086,000. The Board has in a Board meeting decided on the allocation of NOK 5,000,000 between the subsribers. The Company will send information to the subscribers directly regarding their allocation of shares shortly.

New products and solutions to electric commercial vehicles

There is an increasing need and demand for sustainable and cost-efficient technologies in public transport, logistics and industrial production. Electrification and hybridisation of commercial vehicles and mobile machinery offers cost-effective solutions to these and potential gains for process owners and operators. The ECV project entity, coordinated by VTT Technical Research Centre of Finland, has brought together a large number of businesses, research institutions and universities in the field. ECV has contributed in creating domestic products and markets for electric commercial vehicles

Registration of share capital increase in Induct AS

Reference is made to stock exchange notice regarding completion of a private placement in the amount of NOK 10,000,000 dated 19 April 2016 and stock exchange notice regarding completion of the first private placement (NOK 8,000,000 of NOK 18,000,000) dated 2 May 2016. The share capital increase related to the second private placement (NOK10,000,000 of NOK 18,000,000) has now been registered with The Norwegian Register of Business Enterprises. The new share capital in Induct AS is NOK 638,474.80 split by 6,384,748 shares, each with a nominal value of NOK 0.10.

The Competition Authority has approved Inwido’s acquisition of Värmelux in Finland

The Competition Authority has approved Inwido’s acquisition of the Finnish window and door company Värmelux Oy, which owns and operates the Lämpölux brand in Finland. The transaction will be carried out within shortly.The Competition Authority has approved Inwido’s acquisition of the Finnish window and door company Värmelux Oy, which owns and operates the Lämpölux brand in Finland. The transaction will be carried out within shortly.

Appointment of CEO of Norwegian Energy Company ASA

Oslo, 11 May 2016. Reference is made to the stock exchange notice dated 13 October 2015 regarding certain management changes. Silje Augustson has since the day of announcement held the position as group CEO for the Noreco-group in her capacity as executive board member. In order to accommodate for Silje Augustson carrying on with the management of the group’s daily operations, the Board of Directors has today appointed Silje Augustson as general manager and CEO of Norwegian Energy Company ASA, effective from conclusion of the annual general meeting of the company to be held on 26 May 2016.

Annual General Meeting of Fastighets AB Balder (publ)

The Annual General Meeting (AGM) of Fastighets AB Balder (publ) was held on 10 May 2016 in Gothenburg.Christina Rogestam, Chairman of the Board, opened the meeting and was elected Chairman of the AGM.Erik Selin, CEO, reported on the company´s operations during 2015.The income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet for 2015 were adopted. The Board members and the CEO were discharged from liability for their administration during the 2015 fiscal year.The AGM approved the Board of Directors motion that of the

Precise Biometrics algorithm solution integrated in Fingerprint Cards biometric module FPC-BM

Precise BioMatch Embedded has through the collaboration with Fingerprint Cards (FPC) been integrated in FPC-BM, a complete embedded biometric module solution that can be used for a wide range of new applications, including access control, industry and healthcare, automotive, and Internet of Things (IoT).“The biometric module FPC-BM is an innovative product that facilitates integration of fingerprint technology for a range of new products. There is great potential in this market. Precise BioMatch Embedded provides a superior user experience for this type of resource-constrained environments”,

Bulletin from Extraordinary General Meeting of Recipharm AB (Publ)

At the Extraordinary General Meeting (the “EGM”) in Recipharm AB (publ) on 10 May 2016 the shareholders adopted the resolutions summarized below: · On 18 April 2016, Recipharm announced that the Company had signed two separate agreements to acquire Kemwell’s pharmaceutical CDMO businesses. The EGM resolved pursuant to the proposal by the Board of Directors to authorize the Board of Directors, during the period until the next Annual General Meeting (the “AGM”), to issue new series B shares against payment in kind in the form of all shares in Kemwell AB.  · The EGM also resolved to

Glaston to close significant deal with leading float glass expert

GLASTON CORPORATION              Stock exchange release         11 May 2016 at 9.30 (EET)Glaston to close significant deal with leading float glass expertGlaston Corporation has closed a deal for advanced safety glass processing machinery valued at over EUR 2 million with HORN Glass Industries AG, a leading international float glass plant design and construction company. The order is booked in Glaston’s Q2 2016 order book and the lines are delivered during the last quarter of 2016.The deal includes a RC350™ tempering line and ProL™ laminating line. The RC350™ tempering line is well-

Reduced tactile sensitivity on feet of children with diabetes can be found using Multi Frequency Vibrometry

A master's thesis from the Faculty of Medicine at Lund University shows that examined children with type 1 diabetes have reduced tactile sensitivity in the feet compared to children who do not have diabetes. Preliminary data from the study shows that even children and adolescence may have impaired sensation, which may indicate early forms of so-called diabetic neuropathy The discovery was made in an on-going study conducted in collaboration between the Pediatric clinic and the Department of Hand Surgery at Skåne University Hospital in Malmö -Sweden, together with VibroSense Dynamics AB.

Utilization of transfer authorization in Investor AB to secure costs for the Company’s long-term variable remuneration programs

The Annual General Meeting 2016 decided to authorize the Company’s Board to decide on the transfer of the Company’s own shares in order to secure commitments and costs for Investor’s long-term variable remuneration program and for the issue of synthetic shares as part of the Board remuneration. Investor hereby announces that the Company’s Board has decided to utilize the authorization for these purposes. The transfer of own shares may take place on NASDAQ Stockholm during the period from May 11, 2016 up to and including December 2, 2016 at a price within the from time to time registered

Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB (publ) on 10 May 2016 voted to approve the following resolutions: · adoption of the annual report · discharge from liability for the Board members and the Managing Director · a dividend of SEK 5.00 per share · re-election of Board members Jan Annwall, Ewa Björling, David Dangoor, Stefan Elving, Inger Holmström, Anthon Jahreskog, Brit Stakston and Paula Zeilon · re-election of David Dangoor as Board Chairman · re-election of the registered Accounting firm Deloitte AB · Board member compensation in an amount of SEK 300,000 to the

Good start to the year for the Agasti Group

In the first quarter of 2016, the Agasti Group (Agasti) achieved a net income after tax of NOK 5 million, compared to NOK 17 million in the corresponding quarter of 2015. The first quarter of 2016 was the first full quarter with the new group structure, under which Agasti and Blackstone Real Estate Funds respectively own 66 per cent and 34 per cent of the joint venture Obligo Holding AS (Obligo). Agasti’s main source of income is its share of the Obligo Group’s net income after tax, adjusted for amortisations of intangible assets associated with the investment in the joint venture. Since

Europe: united by the Eurovision Song Contest, art – and Kosta Boda!

Art in music, art in glass. A competition brimming over with smiles, love and togetherness – and an event in which Kosta Boda has a natural place. In much the same way as the Eurovision Song Contest, Kosta Boda has always been receptive to what is taking place in the world around it, while also challenging contemporary style through its creative approach. Kosta Boda brought colour to glass, the Eurovision Song Contest brought popular music to a Europe divided between east and west. Together the two unite us all in a mutual European fellowship.On Saturday, the 14 May the final of this year’s

Nye styremedlemmer i LINK Mobility Group ASA

LINK Mobility Group ASA (LINK), Nordens ledende selskap inn mobile meldingstjenester og mobile løsninger for B2C markedet, rigger for videre vekst og henter inn nye erfarne styremedlemmer. LINK som har hatt en formidabel vekst siden selskapet ble notert på Oslo Axess i desember 2013, har klare planer for videre vekst, både organisk og gjennom ytterligere oppkjøp i det sterkt voksende markedet for mobile tjenester. På selskapet generalforsmaling sist uke ble det valgt 2 nye styremedlemmer som med sin kompetanse og erfaring skal bidra til den ambisiøse videutviklingen av LINK, Erik

Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder

Princeton, New Jersey and Lund, Sweden — 11 May 2016 — Braeburn Pharmaceuticals and Camurus today announce top line results of a multiple-dose, pivotal Phase 2 study assessing the blockade by CAM2038 of subjective opioid effects of multiple randomized hydromorphone challenges in adults with opioid use disorder. A key objective of medication-assisted treatment for opioid use disorder is to reduce or eliminate the use of illicit opioids. The results from the present Phase 2 study demonstrate that CAM2038 blocks effectively the subjective effects of opioid challenges with hydromorphone,

Eltel Group: Interim Report January–March 2016

January–March 2016 · Net sales amounted to EUR 287.5 million (239.0), up 23.2%* in local currencies, organic net sales decreased by 0.4%* · Operative EBITA amounted to EUR 3.2 million (5.3) or 1.1% of net sales (2.2) · No non-recurring items (-2.6) · EBITA amounted to EUR 3.2 million (2.7) or 1.1% of net sales (1.1) · Net financial expenses decreased to EUR -3.7 million (-7.9) · The net result amounted to EUR -3.6 million (-7.5) · Earnings per share was EUR -0.06 (-0.14) · Operative cash flow amounted to EUR -37.4 million (-59.9), cash conversion was 112.1% on a

Exel Composites Plc’s Business Review for January 1 – March 31, 2016: Profitability impacted by low volumes in the first quarter; updated outlook for full year 2016

EXEL COMPOSITES PLC       STOCK EXCHANGE RELEASE  11 MAY 2016 at 9.00 A.M. EET Exel Composites Plc’s Business Review for January 1 – March 31, 2016: Profitability impacted by low volumes in the first quarter; updated outlook for full year 2016      Q1 2016 in brief -- Order intake for the first quarter decreased by 20.8% to 18.0 (22.8) MEUR.-- Revenue for the first quarter decreased by 16.6% to 17.9 (21.5) MEUR.-- Operating profit amounted to 0.1 (2.0) MEUR, which is 0.8% (9.3) of revenue.-- Net cash flow from operating activities was negative at -0.9 (+0.7) MEUR.--

LeoVegas AB: First quarter: 1 January-31 March 2016

Stock market introduction, strong growth and good profitability First quarter: 1 January-31 March 2016  · Revenue grew 85.9% to EUR 29.5 m (15.9). Revenue was negatively affected by currency effects totalling EUR 0.5 m. Growth was entirely organic. · Mobile deposits accounted for 61% (54%) of total. · Customer deposits increased by 73% to EUR 80.5 m (46.5). The number of depositing customers was 121,615 (65,122), an increase of 87%. · EBITDA amounted to EUR -1.3 m (0.2), corresponding to an EBITDA margin of -4.4% (1.0%). Earnings were charged with costs of SEK 5.3 m in

Orkla ASA: Mandatory notification of trade - options

On 10 May, in connection with Orkla's former management option programme, 12,500 options in Orkla-shares were exercised at a strike price of NOK 33.88 per share.After this transaction, the total number of options issued in Orkla shares under the management option programme is 1,430,000. Orkla owns 1,648,135 treasury shares.   Orkla ASAOslo, 11 May 2016Ref.:Investor RelationsElise HeidenreichTel.: +47 951 41 147 This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

MSAB: Annual General Meeting Notice 2016

The Annual General Meeting in MSAB on 10 May, 2016 decided to: · Adopt the income statement and the balance sheets as presented in the Annual Report, and to discharge from liability the Board of Directors and the Chief Executive Officer. · Adopt the Board’s proposal to distribute a dividend of SEK 2.20 per share. MSAB B will trade ex-dividend as of 11 May, 2016. The dividend payment date is set to 17 May, 2016. · Re-elect Henrik Tjernberg as Chairman of the Board, and Katarina G. Bonde, Jan-Olof Backman, Örjan Gatu and Robert Ahldin as ordinary Board members, and elect Carl Bildt.

Record date for the reverse share split of the company’s shares

The Annual General Meeting in BE Group AB (publ) on 28 April 2016 resolved on a reverse share split of the company’s shares, whereby 20 existing shares will be consolidated into to one new share (reverse share split 1:20). The Board of Directors was authorized to determine the record date for the reverse share split. The Board of Directors has now determined that the record date for the reverse share split will be Friday 20 May 2016, which means that the last day for trading in the share prior to the reverse share split is Wednesday 18 May 2016, and the first day for trading with the

2016 guidance raised based on solid sales performance and improved profitability

HIGHLIGHTS· Revenue reached DKK 3,770 million in the first quarter of 2016 representing an increase of 6% both reported and in local currencies compared to the same period last year · Total revenue have delivered a better performance than expected for the quarter primarily driven by key products (Abilify Maintena®, Brintellix®/Trintellix, Northera®, Onfi®, Rexulti®) and Xenazine · US revenue increased 38% (32% in local currency) to DKK 1,846 million · Revenue in Europe declined 22% (22% in local currencies) to DKK 747 million · International Markets declined 5% (

Turkey’s Medicana Health Group invests EUR 10 million in Elekta cancer treatment equipment

ANKARA, Turkey, May 11, 2016 – Elekta (EKTA-B.ST) announced today that Medicana Health Group, one of Turkey’s largest private health care networks, invests more than EUR 10 million to purchase sophisticated equipment and software to treat cancer.The deal includes Elekta’s Versa HD™ and Synergy Platform linear accelerators as well as MOSAIQ® oncology information systems and Monaco® treatment planning systems. Salih Bilgin, Elekta’s General Manager for Business Unit Turkey, says: “Medicana is a growing hospital network, with increased focus on cancer care. We are very happy to be able to

There are no items matching the current filter
There are no more items matching the current filter
Back to top